Researchers have developed a device that can be implanted into tumors during surgery to test new treatments, providing unprecedented insight into the effects of drugs on glioma tumors. The device, which is designed to be used during standard of care surgery, caused no adverse effects on patients in a phase 1 clinical trial.
SourceBrigham and Women's Hospital·JournalScience Translational Medicine·TypeObservational study·DateSep 6, 2023
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
SourceMichigan Medicine - University of Michigan·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateAug 31, 2023
Researchers at Michigan Medicine have discovered a potential treatment for diffuse midline glioma, a type of childhood brain tumor with no effective treatments. The compound ONC201 nearly doubled survival rates in patients with the disease, and the underlying mechanism behind its success has been explained.
SourceMichigan Medicine - University of Michigan·JournalCancer Discovery·TypeRandomized controlled/clinical trial·DateAug 16, 2023
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateAug 2, 2023
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A study by Dana-Farber Cancer Institute researchers found that gliomas can arise from epigenetic changes, which affect gene activity without altering DNA sequence. The findings pinpoint two genes, an oncogene and a tumor suppressor, whose activities are epigenetically altered in human gliomas.
SourceDana-Farber Cancer Institute·JournalCell·DateJul 25, 2023
Researchers have developed a technology to capture and release cell-free DNA from urine using nanowire surfaces, successfully detecting IDH1 mutation in glioma patients. This method opens possibilities for the detection of other tumor mutations and could revolutionize cancer diagnosis.
SourceNagoya University·JournalBiosensors and Bioelectronics·DateJul 2, 2023
Researchers have made a significant finding in detecting brain tumors by exploiting folate receptors. Folate receptor expression is significantly higher in glioma tissue compared to adjacent healthy brain tissue, presenting a promising target for future treatments.
SourceUniversity of Turku·JournalFrontiers in Immunology·DateJun 15, 2023
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateJun 4, 2023
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
SourceDana-Farber Cancer Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 4, 2023
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
SourceUniversity of California - Los Angeles Health Sciences·DateMay 22, 2023
Researchers at Cold Spring Harbor Laboratory have developed a potential therapeutic for diffuse intrinsic pontine glioma (DIPG) using antisense oligonucleotide technology. The treatment has slowed tumor growth, reversed changes in cancer cells, and increased survival rates in mice with DIPG.
SourceCold Spring Harbor Laboratory·JournalScience Translational Medicine·DateApr 12, 2023
Researchers developed an AI-based diagnostic screening system called DeepGlioma to analyze tumor specimens and detect genetic mutations rapidly. The system identified molecular subgroups with high accuracy and has the potential to improve access and speed of diagnosis for patients with deadly brain tumors.
SourceMichigan Medicine - University of Michigan·JournalNature Medicine·TypeComputational simulation/modeling·DateMar 23, 2023
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateMar 22, 2023
A team of researchers at Baylor College of Medicine found that glioma-related epilepsy is driven by IGSF3-mediated potassium dysregulation. This disruption leads to seizure activity, which favors disease progression. The study used human patients and animal models to confirm the findings.
SourceBaylor College of Medicine·JournalNeuron·TypeExperimental study·DateFeb 14, 2023
Researchers at Michigan Medicine discovered a gene, ZMYND8, that contributes to the survival of mutant IDH1 glioma cells in response to radiation. Knocking out ZMYND8 renders the cells radiosensitive, offering a new therapeutic avenue for patients.
SourceMichigan Medicine - University of Michigan·JournalClinical Cancer Research·TypeExperimental study·DateJan 24, 2023
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers tracked 392 patients with diffuse low-grade glioma over 20 years and found that aggressive surgical removal offered a distinct survival advantage. Smaller tumor sizes were associated with longer survival times, highlighting the importance of early intervention.
SourceUniversity of California - San Francisco·JournalJournal of Clinical Oncology·DateJan 4, 2023
A new AI tool developed by Brigham and Women's Hospital improves the accuracy of time-critical pathology diagnostics during surgery. The tool, which leverages deep-learning technology, translates frozen tissue samples into high-quality images, increasing diagnostic accuracy and reducing the need for lengthy laboratory tests.
SourceBrigham and Women's Hospital·JournalNature Biomedical Engineering·TypeObservational study·DateDec 23, 2022
A study using spatial single-cell transcriptomics reveals the spatial organization of cancer cells in patient tissues across ages and locations. The research highlights age- and location-dependent differences in tumor biology, suggesting that kids and adults with diffuse midline gliomas may need different treatments.
SourceBoston Children's Hospital·JournalNature Genetics·DateDec 5, 2022
Researchers developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, revealing a promising outlook for long-term survival through radiation therapy combined with small-molecule inhibitors. The treatment approach also showed immune memory, allowing mice to eliminate new tumor growth without additional treatment.
SourceMichigan Medicine - University of Michigan·JournalJournal of Clinical Investigation·TypeExperimental study·DateNov 15, 2022
Advanced nanoparticles carrying a bacterially derived compound target the STING pathway, disrupting blood vessels and stimulating an immune response. This approach suppresses tumor growth and metastasis in several types of cancers.
SourceUniversity of Chicago·JournalNature Nanotechnology·TypeExperimental study·DateOct 27, 2022
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 26, 2022
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
SourceLouisiana State University Health Sciences Center·DateOct 11, 2022
Researchers discovered that animal models with germline alteration rs55705857 developed gliomas significantly faster than those without the alteration. The study offers new insights into tumor formation and may lead to novel therapies targeting this specific change.
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
A new study found that high-grade gliomas remodel the surrounding brain environment to protect tumour cells and hide them from the body's defences. Lower grade tumours often develop a new mutation allowing rapid cell division, potentially progressing to higher grade forms.
A multi-institutional team assessed the diagnostic criteria for canine glioma using the Comparative Brain Tumor Consortium's guidelines. The study found that consensus was achieved for 71 out of 85 cases (84%), with a moderate level of inter-pathologist agreement.
SourceNorth Carolina State University·JournalVeterinary and Comparative Oncology·TypeData/statistical analysis·DateAug 15, 2022
Researchers have developed an immunity-boosting postoperative treatment that could prevent glioblastoma relapse by targeting cancer stem cells with nanoparticles. The injectable gel promotes the cancer-killing immune response and reduces toxic side effects.
SourceUniversity of Wisconsin-Madison·JournalScience Translational Medicine·DateAug 8, 2022
Researchers at Massachusetts General Hospital have developed a blood test that can detect multiple mutations associated with brain cancer, including EGFRvIII. The test showed high sensitivity and specificity, making it a powerful tool for diagnosing gliomas and monitoring tumor progression.
SourceMassachusetts General Hospital·JournalClinical Cancer Research·TypeExperimental study·DateJul 18, 2022
Updated long-term results from Phase III trials demonstrate significant benefits from combining procarbazine, lomustine, and vincristine chemotherapy with radiation therapy for patients with anaplastic oligodendrogliomas. Patients with chromosome 1p19q codeleted tumors experienced improved overall survival and progression-free survival.
SourceNRG Oncology·JournalJournal of Clinical Oncology·DateJun 28, 2022
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
SourceMichigan Medicine - University of Michigan·JournalACS Nano·TypeExperimental study·DateMay 26, 2022
A study from the University of Pittsburgh found that methionine restriction can slow down the growth of difficult-to-treat brain tumors in children, known as diffuse midline gliomas. The researchers discovered that these tumors are uniquely dependent on methionine, an amino acid, and that depleting it can repress cancer cell growth.
SourceUniversity of Pittsburgh·JournalNature Cancer·DateApr 14, 2022
Pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries during the COVID-19 pandemic. The study found that patients in LMICs had 35.7 times the risk of all-cause mortality compared to those in HICs.
SourceAmerican Association for Cancer Research·JournalBMJ Open·DateApr 11, 2022
Researchers discovered a novel mechanism for miR-10b activation in high-grade gliomas, implicating topologic reorganization of chromatin and long-non-coding RNAs. This finding suggests new RNA-targeted strategies for glioma therapy and points to the vulnerability of tumor-initiating cells.
SourceBrigham and Women's Hospital·JournalMolecular Cell·TypeExperimental study·DateApr 6, 2022
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
Post-surgery patients exhibit moderate speech disorders affecting all language processing aspects, whereas post-stroke patients display specific phonological deficits. Understanding these differences is crucial for developing targeted therapies.
SourceNational Research University Higher School of Economics·JournalBrain and Language·DateApr 1, 2022
Researchers collected hundreds of cerebrospinal fluid samples from patients with Diffuse Midline Glioma, tracking changes in cell-free tumor DNA over time. The findings suggest that this method could provide data about tumors sooner than MRIs alone, allowing clinicians to address aggressive brain cancer more effectively.
SourceMichigan Medicine - University of Michigan·JournalNeuro-Oncology·TypeExperimental study·DateMar 24, 2022
A UC researcher is leading three projects to study the genetic workings of deadly pediatric brain tumors, including DIPG. The goal is to understand how genes regulate blood vessels and develop more effective treatments. Researchers are also exploring a new drug that targets a specific genetic mutation.
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
SourceMichigan Medicine - University of Michigan·JournalCell Reports·TypeExperimental study·DateJan 19, 2022
Research reveals that the parietooccipital fissure acts as an obstacle to glioma invasion, with tumor cells making a detour around it. This finding highlights the importance of this fissure in determining the invasion pattern of posterior medial temporal gliomas.
SourceJournal of Neurosurgery Publishing Group·JournalJournal of Neurosurgery·TypeObservational study·DateDec 14, 2021
Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.
SourceWashU Medicine·JournalNature Communications·TypeExperimental study·DateDec 10, 2021
Researchers have found a small-molecule inhibitor that can suppress tumor growth in animal models of H3.3G34R/V glioma, offering new treatment options for pediatric patients. The compound has the potential to cross the blood-brain barrier and is currently being tested in clinical trials.
SourceMichigan Medicine - University of Michigan·JournalScience Translational Medicine·TypeExperimental study·DateOct 13, 2021
Researchers at Weill Cornell Medicine have profiled individual cells from patients' brain tumors in unprecedented detail, revealing distinct states and programming marks that could be targeted with future drugs. The study offers insights into glioma dynamics and may lead to better detection, staging, monitoring, and treatment methods.
SourceWeill Cornell Medicine·JournalNature Genetics·DateOct 1, 2021
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
Researchers have identified a common mutation in gliomas that sensitizes them to immunotherapy, which can lead to improved survival rates and tumor-free periods. The discovery may have broader therapeutic implications for all glioma patients, offering new hope for treatment.
SourceMichigan Medicine - University of Michigan·JournalScience Advances·TypeExperimental study·DateSep 29, 2021
Pediatric oncologist Adam Green and his team have discovered genetic mutations that may predict the development of these secondary tumors, allowing for early detection and alternative treatments. They are also exploring FDA-approved chemotherapy drugs as potential treatments.
SourceUniversity of Colorado Anschutz Medical Campus·JournalNature Communications·DateSep 28, 2021
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
SourceJohns Hopkins Medicine·JournalClinical Cancer Research·DateSep 23, 2021
A team of researchers led by CU Cancer Center member Jean Mulcahy Levy examined tumor samples before and after treatment with a targeted medicine. They found additional mutations that can create resistance to the therapy, highlighting the need for new treatments or combination therapies.
SourceUniversity of Colorado Anschutz Medical Campus·JournalClinical Cancer Research·DateSep 15, 2021
A new study suggests that a treatment for canine glioblastoma may also be effective in humans, with some dogs experiencing significant tumor shrinkage. The treatment uses an immunotherapy drug called STING agonist, which induced a robust immune response against cancer cells.
SourceNorthwestern University·JournalClinical Cancer Research·DateAug 25, 2021
Sky & Telescope Pocket Sky Atlas, 2nd Edition
Sky & Telescope Pocket Sky Atlas, 2nd Edition is a durable star atlas for planning sessions, identifying targets, and teaching celestial navigation.
A new study reveals that high-grade gliomas in dogs contain more immune cells associated with suppressing immune response than low-grade gliomas. The findings suggest that these brain tumors may recruit cells to aid in immunosuppression, which could lead to improved immunotherapies for both humans and dogs.
SourceNorth Carolina State University·JournalVeterinary Pathology·DateAug 19, 2021
A study by the Center for Cell-Based Therapy in São Paulo, Brazil, has discovered a set of biomarkers that can be used to predict which patients with glioblastoma may have tumors resistant to radiation therapy. The genetic signature helps doctors choose the best treatment option for these patients.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalFrontiers in Oncology·DateAug 19, 2021
The study confirms the upregulation of TERT in primary glioblastomas and the gradual expression of all GABP components during malignancy progression. The authors found a positive association between TERT and B1L mRNA expression, highlighting the importance of GABPA/B isoforms in mutated TERT promoter-dependent gliomas.
SourceImpact Journals LLC·JournalOncotarget·DateJul 26, 2021
Researchers discovered that neural activity underlying visual signals can ignite and feed tumors in young children with neurofibromatosis type 1. The study found that raising mice in the dark or treating them with an experimental cancer drug slowed tumor growth, suggesting a key role for controlling neuronal activity.
SourceNIH/National Institute of Neurological Disorders and Stroke·JournalNature·DateJun 1, 2021
Scientists discover a way to reactivate paralyzed immune cells against IDH-mutant gliomas, leading to improved vaccine effectiveness. The researchers identified the molecular mechanism behind the 'immune paralysis' caused by cancer-promoting metabolic products and found a substance that deactivates a key immune system regulatory molecule.
SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalNature Cancer·DateMay 24, 2021
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
Researchers found that female mice with glioma lacking the POT1 gene survived less than males, leading to further investigation of human glioma cells. Low POT1 expression correlated with reduced survival in females, suggesting immune response and tumor cell proliferation played a role in tumor growth.
SourceBaylor College of Medicine·JournalCancer Research·DateApr 19, 2021
A clinical trial tested a mutation-specific vaccine against IDH1-mutated gliomas, a type of diffuse brain tumor. The vaccine proved safe and triggered the desired immune response in 93% of patients, with some experiencing pseudoprogression and tumor growth slowing.
SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalNature·DateMar 24, 2021
A novel gene therapy has been developed to convert glioma cells into functional neurons, offering a new approach to treating the disease. This technology may prolong treatment time by arresting rapid proliferation of malignant glioma cells.
SourceGuangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University·JournalCancer Biology and Medicine·DateMar 23, 2021
A new glioma-targeted nano-therapeutic developed by UH researcher Sheereen Majd delivers the highly toxic anti-cancer drug Dp44mT directly to brain tumor cells, reducing toxicity and improving treatment outcomes.
SourceUniversity of Houston·JournalAdvanced Healthcare Materials·DateFeb 23, 2021
A novel combination treatment approach has shown encouraging results in mice with tumors similar to human astrocytomas. The treatment, which blocks D-2-HG production and inhibits an immune checkpoint protein, led to tumor regression in 60% of treated animals, improving survival rates.
SourceNIH/National Institute of Neurological Disorders and Stroke·JournalJournal of Clinical Investigation·DateFeb 16, 2021
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
Researchers developed a new method to classify brain tumors using RNA analysis, achieving high accuracy rates compared to traditional methods. The study found that this approach can identify patients with a worse prognosis and detect secondary glioblastomas not detected by other methods.
SourceMedical College of Georgia at Augusta University·JournalScientific Reports·DateJan 19, 2021
A new study suggests a link between Toxoplasma gondii infection and the risk of glioma, a type of brain cancer, in adults. Researchers found that people with glioma were more likely to have antibodies to T.gondii than those without the disease.
SourceAmerican Cancer Society·JournalInternational Journal of Cancer·DateJan 11, 2021
Researchers have developed a portable DNA sequencing technology to detect tumor DNA in cerebrospinal fluid, allowing for rapid and reliable monitoring of high-grade gliomas. This approach overcomes traditional barriers to diagnosing and treating pediatric brain cancer, offering a non-invasive alternative to invasive surgeries.
SourceMichigan Medicine - University of Michigan·JournalClinical Cancer Research·DateOct 21, 2020
Researchers at Massachusetts General Hospital have developed a non-invasive liquid biopsy test that can detect genetic mutations in brain tumor patients. The test, which improved detection sensitivity by tenfold, has the potential to revolutionize glioma diagnosis and monitoring.
SourceMassachusetts General Hospital·JournalClinical Cancer Research·DateOct 14, 2020
Apple iPad Pro 11-inch (M4)
Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.
Researchers at FEFU are working on genetically modified models of brain tumors to understand the role of IDH1 and TP53 gene mutations. They plan to create laboratory models of these mutations to develop new diagnostic markers and test antitumor compounds, potentially leading to personalized therapy for glioma patients.